Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
An open label, randomized controlled study in a Norwegian population with meibomian gland
dysfunction. Patients will be randomized to one of two groups: THERA°PEARL Eye Mask (Bausch &
Lomb Inc., New York, USA) or Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield,
UK). All patients will receive Hylo-comod (URSAPHARM Arzneimittel GmbH, Saarbrücken,
Germany).
Phase:
Phase 4
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Schepens Eye Research Institute The Norwegian Dry Eye Clinic